Floatz logo

Alirocumab

Hypercholesterolemia

Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Hypercholesterolemia cohort.

Asset / SponsorPhaseRating
Ezetimibe
Punjab Institute of Cardology
Phase 4BBB
Lipitor
Punjab Institute of Cardology
Phase 4BBB
SIMVASTATIN
paresh Dandona
Phase 4BBB
PITAVASTATIN
JW Pharmaceutical
Phase 4BBB
PRAVASTATIN
Yokohama City University Medical Center
Phase 4BB

View all 36 →

Same molecule, other indications

Alirocumab is also rated in:

inherited lipid metabolism disorderDormant
BB
Indicative ·
66 / 100
View asset →
acute coronary syndromeDormant
BB
Indicative ·
65 / 100
View asset →
PCSK9 InhibitorDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →